

KRAS2 Antibody (C-term)

Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP16005b

Product Information

Application WB, E Primary Accession P01116

Other Accession P08644, P32883, NP 203524.1, NP 004976.2

Reactivity Human, Mouse

Predicted Rat
Host Rabbit
Clonality Polyclonal
Isotype Rabbit IgG
Clone Names RB14572
Calculated MW 21656
Antigen Region 158-185

Additional Information

Gene ID 3845

Other Names GTPase KRas, K-Ras 2, Ki-Ras, c-K-ras, c-Ki-ras, GTPase KRas, N-terminally

processed, KRAS, KRAS2, RASK2

Target/Specificity This KRAS2 antibody is generated from rabbits immunized with a KLH

conjugated synthetic peptide between 158-185 amino acids from the

C-terminal region of human KRAS2.

Dilution WB~~1:1000 E~~Use at an assay dependent concentration.

Format Purified polyclonal antibody supplied in PBS with 0.05% (V/V) Proclin 300. This

antibody is purified through a protein A column, followed by peptide affinity

purification.

Storage Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store

at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions KRAS2 Antibody (C-term) is for research use only and not for use in diagnostic

or therapeutic procedures.

Protein Information

Name KRAS

Synonyms KRAS2, RASK2

Function Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

(PubMed: <u>20949621</u>, PubMed: <u>39809765</u>). Plays an important role in the regulation of cell proliferation (PubMed: <u>22711838</u>, PubMed: <u>23698361</u>). Plays a role in promoting oncogenic events by inducing transcriptional silencing of tumor suppressor genes (TSGs) in colorectal cancer (CRC) cells in a

ZNF304-dependent manner (PubMed:24623306).

Cellular Location Cell membrane; Lipid-anchor; Cytoplasmic side. Endomembrane system.

Cytoplasm, cytosol


Background

This gene, a Kirsten ras oncogene homolog from the mammalian ras gene family, encodes a protein that is a member of the small GTPase superfamily. A single amino acid substitution is responsible for an activating mutation. The transforming protein that results is implicated in various malignancies, including lung adenocarcinoma, mucinous adenoma, ductal carcinoma of the pancreas and colorectal carcinoma. Alternative splicing leads to variants encoding two isoforms that differ in the C-terminal region.

References

Bruckman, K.C., et al. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 110(5):632-637(2010) Wong, K.K., et al. Am. J. Pathol. 177(4):1611-1617(2010) Irahara, N., et al. Diagn. Mol. Pathol. 19(3):157-163(2010) Carotenuto, P., et al. Pharmacogenomics 11(8):1169-1179(2010) Leventopoulos, G., et al. Clin. Exp. Rheumatol. 28(4):556-557(2010)

Images



All lanes: Anti-KRAS2 Antibody (C-term) at 1:1000 dilution Lane 1: PC-3 whole cell lysate Lane 2: Rat brain lysate Lysates/proteins at 20 µg per lane. Secondary: Goat Anti-Rabbit IgG, (H+L), Peroxidase conjugated (ASP1615) at 1/15000 dilution. Observed band size: 23 KDa Blocking/Dilution buffer: 5% NFDM/TBST.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.